|
Real-time Estimate
Cboe BZX
14:35:27 14/01/2026 GMT
|
5-day change
|
1st Jan Change
|
|
371.20 USD
|
+0.34%
|
 |
-8.97%
|
-6.96%
|
|
01-11 |
Alnylam Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2026
|
CI
| |
01-09 |
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026
|
RE
| |
12-18 |
PeptiDream Inc. and Alnylam Pharmaceuticals, Inc. Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration
|
CI
| |
12-17 |
Alnylam Pharmaceuticals, Inc. Announces to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
|
CI
| |
12-13 |
Bitcoin hoarding company Strategy remains in Nasdaq 100
|
RE
| |
12-11 |
Markets Wanted a Party. The Economy Brought a Reality Check.
|  | |
12-11 |
Alnylam announces partial repurchase of 1.00% convertible senior notes due 2027
|
RE
| |
12-11 |
Alnylam Pharmaceuticals Signs Redemption Deals for Certain 1% Senior Notes Due 2027
|
MT
| |
11-13 |
Worldwide Healthcare improves in first-half; sees lower final dividend
|
AN
| |
11-08 |
Alnylam Pharmaceuticals, Inc. Announces Results from New Post Hoc Analysis of the Helios-B Phase 3 Study of Vutrisiran
|
CI
| |
11-04 |
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million
|
MT
| |
30/10/25 |
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
| |
30/10/25 |
Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2025
|
CI
| |
30/10/25 |
Alnylam beats Q3 revenue estimates, up FY forecast
|
RE
| |
30/10/25 |
Alnylam Pharmaceuticals Swings to Q3 Non-GAAP Earnings, Revenue Increases
|
MT
| |
30/10/25 |
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q3 Revenue $1.25B, vs. FactSet Est of $959.4M
|
MT
| |
30/10/25 |
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $2.90 per Share, vs. FactSet Est of $1.52
|
MT
| |
27/10/25 |
Intellia pauses gene therapy trials after patient suffers liver injury, shares slide
|
RE
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,692,062, According to a Recent SEC Filing
|
MT
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,103,451, According to a Recent SEC Filing
|
MT
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $635,126, According to a Recent SEC Filing
|
MT
| |
03/10/25 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing
|
MT
| |
01/10/25 |
Alnylam Pharmaceuticals, Inc. Announces First Patient Dosed in Zenith Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
|
CI
| |
28/09/25 |
Alnylam Pharmaceuticals, Inc. Announces New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
|
CI
| |
18/09/25 |
Alnylam Joins Alliance for Genomic Discovery
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
